Comparative Pharmacology
Head-to-head clinical analysis: FERAHEME versus FERRISELTZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERAHEME versus FERRISELTZ.
FERAHEME vs FERRISELTZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is a superparamagnetic iron oxide nanoparticle coated with a semisynthetic carbohydrate shell. It serves as a source of iron for hemoglobin synthesis and replenishes iron stores. The iron core is processed intracellularly to release iron, which is then incorporated into hemoglobin or stored as ferritin. The carbohydrate shell is metabolized and eliminated.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
510 mg intravenously once, followed by a second 510 mg dose 3 to 8 days later, not exceeding 1020 mg per course.
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
None Documented
None Documented
Terminal half-life of ferumoxytol (iron core) is approximately 14-21 hours; for the intact nanoparticle (carbohydrate shell), half-life is about 15 hours. Clinically, iron is continuously released and incorporated, extending effects beyond half-life.
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
Renal: minimal (<1% as intact drug); primarily degraded endogenously with iron incorporated into hemoglobin; fecal/biliary elimination of unabsorbed iron is negligible.
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Category C
Category C
Iron Supplement
Iron Supplement